A case of AL type amyloidosis nephropathy treated with sequential chemotherapy

doi:10.3969/j.issn.1004-583X.2021.03.016

Abstract

Abstract:

A male patient with AL type amyloidosis nephropathy was presented. The main clinical manifestations were edema, oliguria, abdominal distension, hypoproteinemia, hyperlipidemia and massive proteinuria. The diagnosis was confirmed by renal biopsy. After the sequential use of “CBD” and “TCD” chemotherapy, the patient's condition improved and good partial remission was achieved. The diagnosis, treatment and prognosis of AL type amyloidosis nephropathy were discussed in the article.

Key words: kidney disease, amyloidosis, drug therapy, combination

CLC Number:

R692

Gao Xinglian, Tong Zongwu, Yang Chongmeng, Zhao Yanhong, Lu Yongxin, Ding Rong. A case of AL type amyloidosis nephropathy treated with sequential chemotherapy[J]. Clinical Focus, 2021, 36(3): 266-269.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.03.016

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I3/266

Figures/Tables 4

References 15

[1]	焦晨峰, 姜玲, 赵丽丽, 等. 芬兰型肾淀粉样变性合并膜性肾病一例[J]. 中华肾脏病杂志, 2020,36(4):312-314.
[2]	Huang XH, Liu ZH. The clinical presentation and management of systemic light-chain amyloidosis in China[J]. Kidney Dis (Basel), 2016,2(1):1-9.
[3]	Prakash J, Brojen T, Rathore SS, et al. The changing pattern of renal amyloidosis in Indian subcontinent: Two decades of experience from a single center[J]. Ren Fail, 2012,34(10):1212-1216. doi: 10.3109/0886022X.2012.723514 pmid: 23009273
[4]	毕春丽, 张磊, 金晓明. 淀粉样变肾病研究进展[J]. 国际免疫学杂志, 2017,40(1):65-69.
[5]	Leung N. To biopsy or not to biopsy, that is the question in myeloma cast nephropathy[J]. Nephrol Dial Transplant, 2016,31:1-3. doi: 10.1093/ndt/gfv294 URL
[6]	李思倩, 朱子璇, 文煜冰, 等. 多发性骨髓瘤管型肾病和肾淀粉样变性的临床特征及预后分析[J]. 基础医学与临床, 2019,39(10):1483-1487.
[7]	中国系统性淀粉样变性协作组, 国家肾脏疾病临床医学研究中心. 系统性轻链型淀粉样变性诊断和治疗指南[J]. 中华医学杂志, 2016,96(44):3540-3548.
[8]	黄湘华. 硼替佐米治疗轻链型淀粉样变性的经验浅谈[J]. 肾脏病与透析肾移植杂志, 2017,26(3):255-256.
[9]	Milani P, Sharpley F, Schönland SO, et al. Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: A European retrospective series of 153 patients[J]. Amyloid, 2020,27(4):231-236. doi: 10.1080/13506129.2020.1767566 URL
[10]	Zumbo G, Sadeghi-Alavijeh O, Hawkins PN, et al. New and developing therapies for AL amyloidosis[J]. Expert Opin Pharmaco, 2016,18(2):139-149. doi: 10.1080/14656566.2016.1274971 URL
[11]	Sanchorawala V, Sun F, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience[J]. Blood, 2015,126(20):2345-2347. doi: 10.1182/blood-2015-08-662726 pmid: 26443620
[12]	林泽宇, 陈文明. 轻链型淀粉样变性的诊断及治疗进展[J]. 白血病·淋巴瘤, 2019,28(1):57-60.
[13]	Nuvolone M, Merlini G. Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis[J]. Expert Opin Ther Targets, 2017,21(12):1095-1110. doi: 10.1080/14728222.2017.1398235 URL
[14]	Blank N, Hegenbart U, Schönland S. Causes and treatment of systemic amyloidosis[J]. Z Rheumatol, 2016,75(2):141-150. doi: 10.1007/s00393-015-0024-8 pmid: 88583477603209274
[15]	Angel-Korman A, Jaberi A, Sanchorawala V, et al. The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis[J]. Amyloid, 2020,27(1):17-24. doi: 10.1080/13506129.2019.1672650 pmid: 31595786